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Abstract
Background: Establishing preclinical models is essential for novel drug discovery in schizophrenia. Most existing
models are characterized by abnormalities in behavioral readouts, which are informative, but do not necessarily
translate to the symptoms of the human disease. Therefore, there is a necessity of characterizing the preclinical
models from a molecular point of view. Selective reaction monitoring (SRM) has already shown promise in
preclinical and clinical studies for multiplex measurement of diagnostic, prognostic and treatment-related
biomarkers.
Methods: We have established an SRM assay for multiplex analysis of 7 enzymes of the glycolysis pathway which
is already known to be affected in human schizophrenia and in the widely-used acute PCP rat model of
schizophrenia. The selected enzymes were hexokinase 1 (Hk1), aldolase C (Aldoc), triosephosphate isomerase (Tpi1),
glyceraldehyde-3-phosphate dehydrogenase (Gapdh), phosphoglycerate mutase 1 (Pgam1), phosphoglycerate
kinase 1 (Pgk1) and enolase 2 (Eno2). The levels of these enzymes were analyzed using SRM in frontal cortex from
brain tissue of PCP treated rats.
Results: Univariate analyses showed statistically significant altered levels of Tpi1 and alteration of Hk1, Aldoc,
Pgam1 and Gapdh with borderline significance in PCP rats compared to controls. Most interestingly, multivariate
analysis which considered the levels of all 7 enzymes simultaneously resulted in generation of a bi-dimensional
chart that can distinguish the PCP rats from the controls.
Conclusions: This study not only supports PCP treated rats as a useful preclinical model of schizophrenia, but it
also establishes that SRM mass spectrometry could be used in the development of multiplex classification tools for
complex psychiatric disorders such as schizophrenia.
Keywords: SRM, MRM, Multiplex, Schizophrenia, Proteomics, Preclinical, Assay, Glycolysis, Multiple reaction monitor-
ing, Selective reaction monitoring
Background
Schizophrenia is a psychiatric disorder of uncertain
etiology that affects about 1% of the world’s population.
It is likely to be caused by a complex crosstalk between
genetic, neurodevelopmental and environmental factors
[1] resulting in the differential expression of several
genes and proteins. The multi-factorial characteristic of
schizophrenia not only hinders its biochemical under-
standing and characterization, but makes it difficult to
establish preclinical models, which are needed urgently
for testing of existing and novel therapies [2]. The cur-
rent evaluation of preclinical models for psychiatric dis-
orders is mostly based on readouts following behavioral
tests which simulate particular features or symptoms of
the disease. However, characteristic schizophrenia symp-
toms, such as hallucinations, delusions and disorganized
thoughts cannot be assessed using these tests. In
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lar fingerprinting approaches can be translated directly
between preclinical and clinical studies.
The blockade of NMDA receptors using drugs such as
phencyclidine (PCP) and ketamine is widely used to
mimic schizophrenia in rodents. The psychosis-inducing
effects of these drugs in humans and the widespread
nature of the NMDA receptor in the brain result in
multiple effects which may resemble the multifactorial
features of schizophrenia [3]. Previous studies have
shown that PCP-treated rats present altered glucose uti-
lization in the limbic regions of their brains [4,5], con-
sistent with findings from post mortem brain studies of
schizophrenia patients [6].
Several brain regions collected from schizophrenia
patients post mortem have been analyzed by other large-
scale profiling techniques such as transcriptomic micro-
arrays [7,8], and proteomic methods including two-
dimensional gel electrophoresis and shotgun mass spec-
trometry [9,10]. These analyses have shown consistent
effects on glycolysis enzymes [11] such as hexokinase 1
(Hk1), aldolase C (Aldoc), triosephosphate isomerase
(Tpi1), glyceraldehyde-3-phosphate dehydrogenase
(Gapdh), phosphoglycerate mutase 1 (Pgam1), phospho-
glycerate kinase 1 (Pgk1) and enolase 2 (Eno2) (Figure 1
[12]). These data also support previous findings of
impaired glucose handling in schizophrenia brains
[13-15]. Although impairments in energy metabolism
seem to be a common trait of psychiatric disorders [16],
disturbances in glycolysis appear to be more specific to
schizophrenia [11]. On the other hand, effects on oxida-
tive phosphorylation have been reported more fre-
quently in brains from patients with major depressive
disorder [17]. It is a requirement that preclinical models
present similar traits to the disease in question. Consid-
ering the largely discovered dysregulation of glycolysis
in schizophrenia brains as well as the evidence of differ-
ential glucose handling in preclinical models, the tar-
geted analysis of glycolysis enzymes is one of the
necessary steps in the molecular characterization of pre-
clinical models of schizophrenia.
Most targeted protein expression analyses are per-
formed using either Western blotting (WB) or enzyme-
linked immunosorbent assay (ELISA) approaches.
Although these methods are effective, both are depen-
dent on antibody availability and neither are suitable for
large-scale validation in their standard formats. More-
over, depending on the quality of the antibody
employed, WB analysis is only considered to be a semi-
quantitative method [18]. An alternative for targeted
protein expression analysis is selective reaction monitor-
ing (SRM) mass spectrometry [or multiple reaction
monitoring (MRM)]. SRM is a mass spectrometry-based
technique which can accurately measure the relative or
absolute concentrations of selected peptides/proteins
down to the attomolar range. In addition, SRM can be
multiplexed, allowing the measurement of peptides from
several proteins in a single experiment. Therefore, this
method has the capability of measuring all components
in a metabolic pathway in a single sample.
In this study, we have performed SRM mass spectro-
metry analysis of the seven glycolysis enzymes listed
above in brain tissues of PCP-treated (1.0 and 2.5 mg/
kg) and control rats. The resulting protein levels were
then assessed using univariate and multivariate analyses,
which showed that the acute PCP model reproduces
some of the glycolytic deficits seen in schizophrenia at
the molecular level.
Results and discussion
SRM data for the seven analyzed glycolytic enzymes in
rats treated acutely with PCP showed significant differ-
ences in the levels of Tpi1 among the 3 groups (p =
0.0101 by the Kruskal-Wallis test) and a trend toward
change for the model for Pgam1 (p = 0.065). The source
of the change was identified by comparing the two ver-
sions of the model to the control rats with corrected
Mann Whitney U p-values (Figure 2). The levels of Tpi1
and Pgam1 were decreased in the frontal cortex of PCP
rats consistent with findings from human post mortem
schizophrenia studies [19]. The levels of Aldoc, Hk1,
Gapdh, Eno2 and Pgk1 were not found to be signifi-
cantly altered in contrast with previous studies of schi-
zophrenia in humans which found significant changes in
the levels of these proteins [19-21].
A sam u l t i f a c t o r i a ld i s o r d e r ,s c h i z o p h r e n i ai sl i k e l yt o
be a consequence of several molecular differences of
small effect [22] triggered by environmental factors [23].
These subtle and sometimes even non-significant mole-
cular differences may be one of the reasons why it has
been difficult to replicate and even determine particular
genes or biomarkers responsible for schizophrenia [24].
However, the combination of these small molecular dif-
ferences may lead to major biological disturbances, espe-
cially if the differentially expressed molecules belong to
the same biochemical pathway. We were therefore inter-
ested in determining whether the combination of the
differential expression of glycolytic enzymes can be used
to differentiate between controls and PCP treated
groups despite the lack of statistical significance at the
univariate level. In addition, we aim to check whether
SRM is a suitable proteomic tool for this task.
In the scores plot (Figure 3a), partial least squares dis-
criminant analysis (PLS-DA) projects all the proteomic
intensity data into a multi-dimensional space according
to the number of analyzed variables - seven in this case.
The plot as a whole is rotated in order to maximize the
separation between the analyzed groups. This is then
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plot. Based on the data of seven glycolytic enzymes, this
data provides a clear separation between the PCP model
and the control group as seen on the scores plot (Figure
3a). The mathematical model suggests that an injection
o f1m go fP C Pi ss i m i l a rt o2 . 5m go fP C Pa st h e
model highlights no separation between the different
PCP injections (Figure 3a). This suggests that the same
molecules were affected at both dosages, most likely
because the same molecular pathways were triggered
above a threshold dosage of PCP. Figure 3b shows the
influence of the proteins on the projection. The values
explain the contribution of each protein to the separa-
tion in the scores plot (Figure 3a). Tpi and Pgam were
the highest contributors to this separation, although Tpi
was more robust than Pgam, which is consistent with
Figure 1 Glycolysis metabolic pathway. The differentially expressed enzymes and metabolites revealed by proteomics in post-mortem human
brains from schizophrenia patients are contrasted in black (by KEGG - http://www.genome.jp/kegg).
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cantly different between animal model and control, with
Pgam trending toward significance. The PLS-DA loading
plot (Figure 3c) presents the relationship between the
different proteins and how they relate to the separation
on the scores plot (Figure 3b), it showed that Gapdh,
H k ,A l d o ca n dE n ow e r ec l u s t e r e dt o g e t h e r .T h i ss u g -
gests a strong correlation of their intensities and may
indicate a link in the abundance of these proteins in the
tissue analyzed (Figure 3c). This is interesting as none
of these molecules showed statistically significant differ-
ences at the univariate level. However, the multivariate
model suggests that they interact as components of the
same pathway in distinguishing the PCP and control
groups.
The translation of academic findings to the clinic is
now a major objective of biomarker validation studies,
especially in support of drug discovery. The Food and
Drug Administration (FDA) has now called for efforts to
modernize methods, tools and techniques for the pur-
pose of delivering more efficacious and safer drugs
[25,26]. SRM mass spectrometry can be optimized for
performing high throughput multiplex analyses, which is
robust and user friendly for use in the clinical environ-
ment, as stated above. Moreover, we have used the mul-
tiplex SRM mass spectrometry approach here to
determine molecular phenotypes of a pre-clinical model
of schizophrenia. This demonstrated the potential of
translating this model for use in drug discovery with a
set of companion biomarkers representing the glycolytic
pathway to facilitate this process.
The validation of large scale proteomic profiling
results has been a bottle neck in biomarker discovery.
This is due in part to the lack of a robust technological
pipeline connecting discovery with validation and trans-
lation, which is applicable to a clinical setting [27].
Here, we have shown that SRM mass spectrometry is a
useful platform for achieving this goal. This approach
has already been used in clinical studies such as those
screening for the levels of dihydroartemisinin (DHA) in
plasma of malaria patients [28], for determining the
levels of apolipoproteins in human plasma [29] and for
cancer biomarker screening [30]. Finally, although in a
Figure 2 Univariate analysis of glycolysis enzymes.M a s s
spectrometry intensities are normalized relative to the spiked
enolase peptides.
Figure 3 Multivariate analyses of glycolysis enzymes analyzed
by SRM. a) Partial least squares discriminant analysis (PLS-DA)
scores plot shows the distribution of the different samples in two
dimensions, it should be noted that both PCP groups were treated
as one class. Good separation was achieved between the model
and the control. Also, the plot shows little difference between the
samples in the 1 mg and 2.5 mg of PCP models. b) Variable
influence on projection (VIP) bar chart shows that Tpi is most
important to the separation, as shown in the scores plot. c) The
loading plot also identifies Tpi as an important analyte for
separation and shows that it is reproducible across samples in a
group. Gapdh, Hk, Aldoc and Eno (inside red circle) cluster tightly
together.
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port a role for the PCP rat as a good model for some
aspects of schizophrenia, including metabolic dysfunc-
tion, as this has shown dysregulation of the glycolysis-
related enzymes as previously shown in brain tissue
from schizophrenia patients.
Limitations of our study include the number of ana-
lyzed samples. Replication for validating the biological
interpretation here is suggested, which can also confirm
the validity of our assessment using PLS-DA. Methodo-
logically, Tpi1 was only analyzed by one peptide. All
other possible Tpi1 peptides were neither proteotypic
[31] nor quantotypic [32] as well as not prone to post-
translational modifications as verified by PHOSIDA
http://www.phosida.com[33].
Conclusions
Previous studies have shown alterations in glucose
uptake in the brain following acute PCP treatment, with
an initial increase within 3 hours, followed by a decrease
lasting up to 2 days [4]. This finding was recently corro-
borated by in vivo NMR spectroscopy [5], which showed
the increased glucose uptake peaked 20 minutes after
PCP injection. However it is not known whether the
increase in glucose concentration is due to increased
uptake through the blood-brain barrier, to decreased
utilization of glucose by the brain, or both. Nevertheless,
these observations support our results considering the
overall differential expression of glycolytic enzymes. The
multivariate model demonstrated how non-significant
variations of several components of a pathway can lead
to a significant biological response, as observed pre-
viously on the behavior of PCP treated animals [34,35].
Such effects may also be likely in the case of schizophre-
nia as conflicting reports have been published on the
expression changes of individual molecules (Table 1 in
[9]).
Our findings warrant further biological research on
the analysis of glycolytic enzymes in other schizophrenia
models, including investigating the effects of drug treat-
ments. Further technical developments should be direc-
ted towards the use of SRM as a multiplex tool for
diagnostic purposes. In addition, pathways representing
other aspects of schizophrenia could be developed using
the SRM format, especially in cases of models where
other pathways are known to be modified.
Methods
Samples
Male, adult Lister Hooded rats (Harlan, Horst, The
Netherlands), weighing 180-220 g were housed in
groups of three to four under standard laboratory condi-
tions at a temperature of 21°C (± 1°C). Rats were main-
tained on a 12-h/12-h light/dark cycle (lights on at
08:00). Experiments were conducted during the light
cycle. Food and water were available ad libitum.A l l
experiments were performed in accordance with the
European Communities Council Directives (86/609/
EEC) and were approved by the policies of the ethical
committee of Johnson and Johnson Pharma (Beerse, Bel-
gium). Rats received an acute subcutaneous injection of
either 1 mg/kg (n = 9) or 2.5 mg/kg (n = 7) PCP as
these dosages have been shown previously to signifi-
cantly enhance locomotion in open field testing [36].
PCP (Johnson and Johnson Pharma, Beerse, Belgium)
was dissolved in 0.9% saline. The control group (n = 5)
received an equivalent volume of saline (Baxter, Bel-
gium). Sixty minutes after PCP or saline administration,
rats were decapitated and brains were dissected immedi-
ately on ice to obtain frontal cortex (FC) samples, which
were stored at -80°C until further use.
Protein extraction
Brain tissue samples were sonicated for 2 minutes in a
buffer containing 7 M urea, 2 M thiourea, 4% CHAPS,
2% ASB14, 70 mM dithiothreitol (DTT) (all from
Sigma) at a 5:1 (v:w) ratio [37] for proteome extraction.
Samples were vortexed for 30 minutes and centrifuged
for 3 minutes at 17000 g at 4°C. Protein concentrations
in the supernatants were determined using a Bradford
assay (Biorad, UK). Extracted proteins (100 mg) were
precipitated overnight using cold acetone (-20°C) and
centrifuged for 10 min at 17000 g at 4°C. The superna-
tants were discarded and the pellets dissolved in 50 mM
ammonium bicarbonate. Next, sulfhydryl groups were
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lowed by alkylation with 10 mM iodacetamide in the
dark at 37°C for 30 minutes. Each resultant proteome
was digested using trypsin at a 1:50 (w:w) ratio for 17
hours at 37°C. Reactions were stopped by addition of
8.8 M HCl at a 1:60 (w:w) ratio. The concentrations of
the digested proteins (also referred to as the peptidome)
were adjusted to 0.1 μg/μL by addition of the appropri-
ate amounts of 0.1% formic acid. Samples were spiked
with 25 fmol of yeast enolase for data normalization.
Mass spectrometry experiments
Peptidomes were injected in duplicate into a nanoUltra
performance liquid chromatography instrument contain-
ing a BEH-130 C18 column (75 um × 200 mm) at a
flow rate of 0.3 μL/min, coupled online to a Xevo-triple-
quadrupole mass spectrometer (Waters; Milford, MA,
USA). The separation buffers were A) 0.1% formic acid
and B) acetonitrile in 0.1% formic acid. For separation
of peptides, the following 48 min gradient was applied:
97/3% (A/B) to 60/40%B in 30 min; 60/40% to 15/85%
in 2 min; 5 min at 15/85%; returning to the initial con-
dition in 1 min. Selected peptides (Table 1) eluting from
the nanoLC were measured in SRM mode using an elec-
trospray voltage of 22 kV and a cone voltage of 30 V.
All SRM functions had a 2 min window of the predicted
retention time and scan times were 20 milliseconds. At
least 2 SRM transitions per peptide were measured. The
collision energy for each transition was optimized using
Skyline software (MacCoss Lab Software; Seattle, WA,
USA) [38] based on the equation: CE = 0.034*m/z
+3.314. Acquired data were processed and quantified
using TargetLynx (Waters). Mass spectral intensities of
peptides from the target proteins were averaged and
normalized against yeast enolase intensities.
Statistical analyses
To account for potential non-Gaussian distributions,
data were assessed using the Kruskal-Wallis test to find
if any differences were present among the three groups.
Significant differences between the two dosages of PCP
and control groups were calculated using corrected
Mann Whitney U p-values, applying the Benjamini-
Hochberg method for multiple testing. All tests were
two-tailed and conducted in Prism 5 (Graphpad Soft-
ware Inc; La Jolla, CA, USA) or R 2.13 (The R Founda-
tion for Statistical Computing, Vienna, Austria).
For the multivariate analyses, partial least squares dis-
criminant analysis (PLS-DA) was used (Simca-P + 12;
Umetrics; Umea, Sweden). PLS-DA is a supervised
method for fine tuning a principle component analysis
(PCA) model to maximize separation between two
groups of observations. The protein intensities were
uploaded to the software which assembled these linearly
to form PLS components that were plotted in multidi-
mensional space. These plots were then reduced to the
principle components which are presented as a two-
dimensional PLS-DA scores plot [39]. In addition to this
2D plot, the software calculates the variable influence
on projection (VIP) which assesses the contribution of
each variable on the separation observed on the PLS-
DA scores plot [40]. Lastly, the loading plot (S-plot) is
presented. The x-axis represents the contribution of
each variable to the separation). Variables positioned
furthest from the centre have the strongest contribution.
The data plotted along the y-axis show the correlation
of each variable from sample to sample (the further the
variable is from the centre, the stronger the correlation
[41]).
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